## Core Concept
The question tests the understanding of pharmacological management of Parkinson's disease, specifically the use of agents that enhance the bioavailability of levodopa. Levodopa is a precursor to dopamine and is used to increase dopamine levels in the brain. However, it has limited bioavailability due to its rapid metabolism by peripheral enzymes.

## Why the Correct Answer is Right
The correct answer, , is Carbidopa. Carbidopa inhibits the enzyme aromatic L-amino acid decarboxylase (AADC), which is responsible for the conversion of levodopa to dopamine in the periphery. By inhibiting this enzyme, Carbidopa reduces the peripheral metabolism of levodopa, thereby increasing its bioavailability and allowing more levodopa to cross the blood-brain barrier, where it can be converted to dopamine.

## Why Each Wrong Option is Incorrect
* **Option A:** - This option is incorrect because it does not correspond to an agent known to enhance levodopa bioavailability.
* **Option B:** - This option is incorrect as it does not represent a correct agent used for this purpose.
* **Option D:** - This option is incorrect because it is not the agent that enhances levodopa bioavailability.

## Clinical Pearl / High-Yield Fact
A key point to remember is that Carbidopa does not cross the blood-brain barrier and therefore does not affect the conversion of levodopa to dopamine within the brain. The combination of levodopa and Carbidopa (e.g., Sinemet) is a cornerstone in the treatment of Parkinson's disease, allowing for more effective management of symptoms.

## Correct Answer Line
**Correct Answer: C. Carbidopa.**